sdbn.org

News, San Diego Union Tribune, Syndication »

Summary Box: Glaxo used ghostwriting to push Paxil
Posted by Mary Canady August 19th, 2009 .
No Comments

British drugmaker GlaxoSmithKline PLC used a ghostwriting operation called CASPPER to promote its antidepressant Paxil, allowing doctors to take credit for journal articles mainly written by company consultants, according to court documents. More...

News, San Diego Union Tribune, Syndication »

Glaxo used ghostwriting program to promote Paxil
Posted by Mary Canady August 19th, 2009 .
No Comments

Drugmaker GlaxoSmithKline used a sophisticated ghostwriting program to promote its antidepressant Paxil, allowing doctors to take credit for medical journal articles mainly written by company consultants, according to court documents obtained by The Associated Press. More...

News, San Diego Union Tribune, Syndication »

Judge rules for Merck on allergy drug’s patent
Posted by Mary Canady August 19th, 2009 .
No Comments

The patent for Merck & Co.'s blockbuster allergy and asthma drug is valid, a federal judge ruled Wednesday, handing the drugmaker a crucial victory in its 2 1/2-year legal battle to block a rival from selling a cheaper generic version. More...

News, San Diego Union Tribune, Syndication »

Mylan sues Pittsburgh paper over document stories
Posted by Mary Canady August 19th, 2009 .
No Comments

Generic drug giant Mylan Inc. has sued the Pittsburgh Post-Gazette over stories based on internal documents that prompted a review by the Food and Drug Administration. More...

News, San Diego Union Tribune, Syndication »

FDA warns Johnson & Johnson on antibiotic trials
Posted by Mary Canady August 19th, 2009 .
No Comments

The Food and Drug Administration warned Johnson & Johnson that it did not properly monitor two tests in people of its antibiotic drug candidate ceftobiprole, which is intended to treat complicated skin infections like MRSA. More...

News, San Diego Union Tribune, Syndication »

Watson offering $850 million in notes
Posted by Mary Canady August 18th, 2009 .
No Comments

Drug developer Watson Pharmaceuticals Inc. said Tuesday it is offering $850 million in a mix of senior notes. More...

News, San Diego Union Tribune, Syndication »

Correction: Eli Lilly osteoporosis drug
Posted by Mary Canady August 18th, 2009 .
No Comments

In an Aug. 18 story about Eli Lilly and Co.'s osteoporosis drug, The Associated Press reported erroneously that the drug failed to meet key study goals. Instead, the drug met the goals, but the company is not seeking Food and Drug Administration approval. More...

News, San Diego Union Tribune, Syndication »

Lilly drug fails study, regulatory filing nixed
Posted by Mary Canady August 18th, 2009 .
No Comments

Eli Lilly says its developing postmenopausal osteoporosis drug did not meet treatment goals in a late-stage study and the company will not seek regulatory approval, resulting in a financial charge. More...

News, San Diego Union Tribune, Syndication »

Adamas signs with US Navy to make flu treatment
Posted by Mary Canady August 18th, 2009 .
No Comments

Adamas Pharmaceuticals Inc. said Tuesday it signed a deal with the Unites States Navy to conduct laboratory studies on a potential combination treatment for a variety of influenza strains, including swine flu. More...

News, San Diego Union Tribune, Syndication »

Moody’s rates Watson note offering as ‘junk’
Posted by Mary Canady August 18th, 2009 .
No Comments

Moody's Investors Service on Tuesday assigned a "junk" rating to Watson Pharmaceuticals Inc.'s $850 million offering of senior notes. More...